NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025.
BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique opportunity for intensive networking, collaboration, and the exploration of promising new partnerships. Covering a broad range of life science research and applications, BIOTEC-CHINA 2025 will spotlight key innovation areas such as drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
NKGen Presentation Details:
Title:
Use of Autologous Enhanced Natural Killer Cells for Alzheimer's and Parkinson's Disease
Location:
Shuijing Hall, Beijing Huanghe Jingdu Conference Center, The Third Building
Date and Time:
April 17, 2025, at 10:20 am – 10:40 am CST (China Standard Time) UTC/GMT +8
Dr. Song will present on the use of troculeucel in the treatment of patients with Alzheimer's and Parkinson's disease, highlighting the promising results previously observed in our Phase 1 clinical trials and compassionate use cases. Additionally, Dr. Song will provide an update on NKGen's ongoing Phase 1/2a clinical trial for moderate Alzheimer's disease, with recent data presented at the AD/PD™ 2025 conference. The favorable clinical outcomes and biomarker data disclosed to date offer strong indications that troculeucel may emerge as a viable treatment option for patients with Alzheimer's and Parkinson's disease.
Previously disclosed data for troculeucel in Alzheimer's disease can be found on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at https://nkgenbiotech.com/news/.
About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.
About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at www.sec.gov and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@nkgenbiotech.com
External Contact:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@lifesciadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WIRED
42 minutes ago
- WIRED
WHO Monitors New Covid Variant Spreading in America and Europe
Jun 10, 2025 5:00 AM NB.1.8.1 has mutations that could increase the virus's transmissibility and decrease the efficacy of certain neutralizing antibodies against it. Photograph: Calvin Chan Wai Meng A new Covid variant is being kept under surveillance by the World Health Organization (WHO) as its emergence has led to an increase in infections in several regions of the world. First identified at the end of January, the variant—called NB.1.8.1 but known informally as 'Nimbus'—is a descendant of the Omicron family of Covid sublineages, and has become increasingly prevalent throughout the spring in Europe, the Americas, and the Western Pacific. The virus has mutations that may increase its infectiousness and allow it to escape certain antibodies. Nevertheless, 'considering the available evidence, the additional public health risk posed by NB.1.8.1 is evaluated as low at the global level,' the WHO wrote in its most recent risk evaluation for the variant. Like other variants before it, Nimbus has specific mutations to its spike protein. These proteins coat the virus's surface and are what it uses to gain entry into cells, where it reproduces. Nimbus' spike protein modifications could increase its transmission capacity and partially reduce the neutralizing efficacy of certain antibodies generated by previous infections, both of which would contribute to its spread. However, the WHO says that there is no evidence that this variant causes more severe disease compared to other strains currently circulating. Nor have increases in hospitalizations or deaths related to its emergence been observed. Symptoms associated with NB.1.8.1 are similar to those caused by other SARS-CoV-2 variants: sore throat, cough, fatigue, fever, muscle aches, loss of taste or smell, respiratory distress, nausea, vomiting, and diarrhea. The WHO experts explain that, although this variant may partially evade some antibody responses, such 'immune escape' is comparable to that observed in other Omicron sublineages. This suggests that the mutations present in NB.1.8.1 do not give the virus increased resistance to antivirals such as nirmatrelvir, and that current vaccines continue to be effective in preventing severe disease when infected with this version of the virus. However, to those most vulnerable to Covid—such as the elderly, immunocompromised, or those with preexisting chronic conditions—Nimbus represents a new health threat, and these groups should stay up to date with booster vaccinations to ensure they are protected against Covid's worst effects. This story originally appeared on WIRED en Español and has been translated from Spanish.
Health Line
an hour ago
- Health Line
Can Turmeric Help You Lose Weight?
Turmeric is a widely used spice with several potential health benefits. While it is thought to help with weight loss, further research in humans is needed to verify this. Turmeric, also known as the golden spice, is popular in Asian cuisine and has been a part of traditional Indian medicine — or Ayurveda — for thousands of years. Most of turmeric's health properties can be attributed to curcumin, a compound that has strong antioxidant and anti-inflammatory properties. Recent studies indicate that turmeric may play a role in weight loss. Learn more about whether turmeric could help with weight loss and how much you would have to take to see results. Turmeric and weight loss Recent research has examined turmeric's role in weight loss. In fact, a 2023 review suggests that curcumin may suppress particular inflammatory markers that play a role in obesity. These markers are typically elevated in people with excess weight or obesity. A 2022 review noted that curcumin is a promising natural compound that may help with weight loss; however, more studies are needed before turmeric can be recommended as a weight management or preventive measure. Turmeric safety and adverse effects In general, turmeric and curcumin are considered safe. The World Health Organization (WHO) suggests a range of 0-3 mg per kilogram of body weight as a safe daily intake. Nonetheless, some people who take large doses of this compound may experience adverse effects, such as: allergic reactions nausea vomiting stomach pain constipation skin rash diarrhea Also, those with the following conditions should avoid turmeric supplements: Bleeding disorders. Turmeric may hinder blood clotting, which may cause issues in people with bleeding disorders. Iron deficiency. Turmeric may hinder iron absorption. Kidney stones. This spice is high in oxalates, which are compounds that may bind to calcium and contribute to kidney stone formation. Note that there's insufficient evidence regarding the safety of these supplements among pregnant or breastfeeding people. Therefore, it's recommended that they avoid them. Moreover, some turmeric products may contain filler ingredients not revealed on the label, so it's best to choose a supplement that has been certified by a third party, such as NSF International or Informed Choice. A healthcare professional can help determine whether turmeric or curcumin supplements are right for you. How to use turmeric Turmeric comes in several forms, though the easiest way to use it is as a cooking spice. It's also enjoyed in beverages like turmeric ginger tea and golden milk, which is made by heating milk, turmeric, ginger, black pepper, and cinnamon powder. In Indian cuisine, turmeric is commonly consumed in tea with black pepper and other ingredients like honey, ginger, olive oil, and coconut oil. That said, most human studies suggest that health benefits are only seen at higher doses, such as those found in turmeric extracts or curcumin supplements. That's because turmeric contains a very small amount of curcumin, whereas extracts pack a bigger punch of curcumin. You may want to choose a supplement that includes black pepper, as its compounds significantly improve curcumin absorption. Although there are no official dosage guidelines for these supplements, recent research suggests that 400–600 mg of a standard curcumin powder can be taken up to three times a day to see potential benefits. However, you should avoid taking high doses of turmeric for longer than three months at a time, as long-term safety research is unavailable.
Yahoo
5 hours ago
- Yahoo
Why has there been a global surge of new Covid variant NB.1.8.1?
India is the latest country to report a surge in new Covid cases, as the latest variant, NB.1.8.1, spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UK Health Security Agency recorded the first 13 cases in England last week. But the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent a month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at UK private healthcare centre Pall Mall Medical, said: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, the 'Nimbus' variant, as it has been dubbed, does appear to be more transmissible than previous strains, with notable increases reported in India, Hong Kong, Singapore and Thailand, notes Dr Asif. Common symptoms of Nimbus include a severe sore throat, fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.
